BOPA Guidance on use of H2 antagonists for hypersensitivity

In response to the nationwide shortage of ranitidine and other H2 antagonists, BOPA have produced a guideline on the use of H2 antagonists for the prevention and management of hypersensitivity to assist with clinical decision making.

Click here to view the guideline.

We are also planning a national service evaluation to monitor the impact of the shortage – details to follow soon. Watch this space!

Latest News

By BOPA Committee on 22nd October 2021

BCS/BCOS/UCLH Cancer Academy Cardio-Oncology Course – 18th November 2021

BCS/BCOS/UCLH Cancer Academy Cardio-Oncology Course   Building on the success of the cardio-oncology talk at BOPA2021 please see BCS/BCOS/UCLH Cancer Academy Cardio-Oncology Course taking place on 18th November 2021. If…

Read article
By BOPA Committee on 21st October 2021

Lets Communicate Cancer – Award Nomination

BOPA’s ‘Lets Communicate Cancer’ Programme and been shortlisted for the @ChemistDruggist ‘Training and Development Award’ 2021 (https://www.chemistanddruggist.co.uk/Awards/shortlist).  Access LCC for FREE below – https://bopa.org.uk/lessons/showreel-note-you-must-be-at-least-a-free-member-to-access-this-course-join-here/… #CDAwards #CDAwards2021 Thank you to Jackie…

Read article
By Alia Nizam on 15th October 2021

Breast regimen-specific consent forms

Dear All,   I am pleased to inform you that the breast regimen-specific consent forms have been updated with the following: Subcutaneous administration option for regimens containing Trastuzumab  and Pertuzumab.…

Read article
By BOPA Committee on 12th October 2021

2022 – save the dates

The 25th BOPA symposium will take place in Liverpool on 7th to 9th October 2022. We hope you finally SEE you there!

Read article

25th BOPA Symposium 2022

7th to 9th October 2022 at The ACC Liverpool

SAVE THE DATE!

Everything you need to know